Ramy Rahmé - Concepedia

Author

Ramy Rahmé

Hôpital Saint-Louis ORCID

Also Known As

R Rahmé, R. Rahme, Rahmé, Ramy, Ramy Rahme, Ramy Rahmé

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

Hôpital Saint-Louis Assistance Publique – Hôpitaux de Paris Inserm Université Paris Cité Centre Méditerranéen de Médecine Moléculaire

About

Ramy Rahmé is an author at Hôpital Saint-Louis specializing in radiation oncology, hematology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	1	1	19
2	Medicine	1	1	19
3	Immunology	1	1	19
4	Pathology	1	1	19
5	Hematology	1	1	19

Ramy Rahmé

Publications

953

Citations

H-Index

Page 1

	Year	Citations
Eprenetapopt Plus Azacitidine in <i>TP53</i>-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM) Thomas Cluzeau, Marie Sébert, Ramy Rahmé, Journal of Clinical Oncology	2021	256
Germline DDX41 mutations define a significant entity within adult MDS/AML patients Marie Sébert, Marie Passet, Anna Raimbault, Blood	2019	202
Synergistic effects of PRIMA-1<sup>Met</sup> (APR-246) and 5-azacitidine in <i>TP53</i>-mutated myelodysplastic syndromes and acute myeloid leukemia Nabih Maslah, Norman Salomao, Louis Drevon, Haematologica	2019	135
Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort Edmond Chiche, Ramy Rahmé, Sarah Bertoli, Blood Advances	2021	107
APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des Myélodysplasies (GFM) Thomas Cluzeau, Marie Sébert, Ramy Rahmé, Blood	2019	65
Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide—an International Collaborative Study Sabine Käyser, Ramy Rahmé, David Martínez‐Cuadrón, Leukemia	2020	49
FLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemias Cécile Esnault, Ramy Rahmé, Kim L. Rice, Blood	2019	44
Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with <i>TP53</i> mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML) David A. Sallman, Rami S. Komrokji, Amy E. DeZern, Blood	2021	41
Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study Sabine Käyser, Richard F. Schlenk, Delphine Lebon, Haematologica	2021	21
Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy Marco Cerrano, Matthieu Duchmann, Rathana Kim, Leukemia Hematological MalignancyClonal DominanceMedicineAcute Myeloid LeukemiaMixed-phenotype Acute Leukemia	2020	19

Page 1